A phase Ib study of preoperative lapatinib, paclitaxel, and gemcitabine combination therapy in women with HER2-positive early breast cancer.
I. H. Park
No relevant relationships to disclose
K. S. Lee
No relevant relationships to disclose
H. S. Kang
No relevant relationships to disclose
Y. Kwon
No relevant relationships to disclose
S. W. Kim
No relevant relationships to disclose
S. Lee
No relevant relationships to disclose
S. Y. Jung
No relevant relationships to disclose
K. H. Shin
No relevant relationships to disclose
K. Ko
No relevant relationships to disclose
B. Nam
No relevant relationships to disclose
J. Ro
Consultant or Advisory Role - GlaxoSmithKline (U); Pfizer (U)
Honoraria - GlaxoSmithKline; Pfizer
Research Funding - GlaxoSmithKline